{"schema_version":"secwatch.filing_event.v1","accession":"0001688757-22-000098","form_type":"8-K","ticker":"ESTA","cik":"0001688757","company_name":"ESTABLISHMENT LABS HOLDINGS INC.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.713256+00:00","generated_at":"2026-06-22T05:33:41.468218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Establishment Labs Q3 revenue $38.2M (+31.7% YoY); tightens 2022 guidance to $158-162M","bullets":["Q3 revenue $38.2M, up 31.7% YoY (37.7% constant currency); net loss $10.5M vs $9.0M in Q3 2021.","Gross margin improved to 68.1% from 67.6%; operating expenses rose 27.5% to $36.6M.","2022 revenue guidance tightened to $158-162M from $155-165M; constant-currency growth 30-33% YoY.","Cash balance $65.3M as of Sep 30; expects Mia Femtech launch and China approval in 1H 2023.","Plans to submit Motiva Implants for U.S. FDA approval in Q4 2022; all U.S. IDE trial cohorts enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001688757-22-000098","json":"https://secwatch.observer/filing/0001688757-22-000098.json","markdown":"https://secwatch.observer/filing/0001688757-22-000098.md","text":"https://secwatch.observer/filing/0001688757-22-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1688757/000168875722000098/0001688757-22-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1688757/000168875722000098/esta-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:33:41.468218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e7471327e9659828a7ea3e0b54197d582b8e541","claim":"ESTABLISHMENT LABS HOLDINGS INC. reported the third quarter ended September 30, 2022 results: revenue $38.2 million, net income Net loss from operations for the third quarter was $10.5 million.","evidence_excerpt":"and reconstruction, today announced its financial results for the third quarter ended September 30, 2022. Third Quarter Highlights and Outlook • Third quarter worldwide sales of $38.2 million, an increase of 31.7% year-over-year; excluding the impact of foreign currency changes, revenue growth in the third quarter would have been 37.7%. • Revenue guidance for 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1688757/000168875722000098/0001688757-22-000098-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$38.2 million"},{"label":"Net income","value":"Net loss from operations for the third quarter was $10.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}